SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04362644
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
The purpose of the study is to see if imaging with [18F]FDG and [18F]DPA-714 using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
NCT04362644 Idiopathic Pulmonary Fibrosis MeSH:Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis
1 Interventions
Name: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Primary Outcomes
Measure: Correlate quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests. Time: screening to 48 hours post 2nd imaging visit.Purpose: Diagnostic
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 rs6971
4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70. 5. High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971.
Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.